10 Year Outcomes From A Single-Centre Experience Of Sunitinib And Pazopanib As First-Line Treatment Of Metastatic Renal-Cell Carcinoma (Mrcc).

e16085Background: Sunitinib (S) and Pazopanib (P) have become the standard of care in the management of mRCC supported by clear therapeutic benefits in clinical trials. We set out to evaluate and compare the efficacy and survival outcomes of these two agents used in our centre. Methods: mRCC patients who received either these agents as first line treatment both in standard clinical (n=577) or trial (n=88) setting in our centre (2005-2015) were identified through the Renal Cancer Database. Outcomes of interest include response rate PFS and particularly long-term survival. Subgroup analysis were performed based on prognostic variables to assess survival impact. Results: A total of 665 patients were identified (S=397, P=268). Baseline demographic were balanced between the groups but there were more patients with poorer performance status (PS 2-3) and prognostic risk categories (MSKCC Memorial Sloan Kettering Cancer Centre and Heng et al 2009) in P than in S group at 31% v 19% and 21% v 15% respectively. Over...